Key Points AbbVie survived Humira’s patent cliff. Its new billion-dollar drugs are picking up the slack. 10 stocks we like better than AbbVie › AbbVie (NYSE: ABBV) , one of the world's largest pharmaceutical companies , has been a reliable long-term investment. It's raised its dividend annually for 53 consecutive years, making it a Dividend King that has increased its payout for at least 50 years in a row, and a dozen of its drugs generate more than $1 billion in annual revenue. But as the 10-year Treasury yield stays above 5% -- its highest level since 2007 -- is it still smart to buy and hold this dividend stock? Image source: Getty Images. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。